Last reviewed · How we verify
IOA-244
At a glance
| Generic name | IOA-244 |
|---|---|
| Sponsor | iOnctura |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) (PHASE1, PHASE2)
- A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (PHASE1, PHASE2)
- A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients (PHASE1, PHASE2)
- A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma (PHASE2)
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOA-244 CI brief — competitive landscape report
- IOA-244 updates RSS · CI watch RSS
- iOnctura portfolio CI